SCHEMBL21783435

SCHEMBL21783435

CC(C)(C)OC(=O)Nc1cc(F)c(SCc2ccccc2)nc1C1CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.40
GAA P10253 1/20 0.40
THRB P10828 1/20 0.40
SCN9A Q15858 1/20 0.39
TSHR P16473 4/20 0.39
ALDH1A1 P00352 4/20 0.39
LMNA P02545 3/20 0.39
HSD17B10 Q99714 1/20 0.39
POLB P06746 2/20 0.39
SLC29A1 Q99808 1/20 0.38
IDO1 P14902 1/20 0.38
BRAF P15056 1/20 0.38
BRD4 O60885 1/20 0.37
PPARG P37231 3/20 0.37
PPARA Q07869 1/20 0.37
ABCC8 Q09428 1/20 0.36
KCNJ11 Q14654 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30046068 1.00 NPSR1 (0.42) NPSR1KMT2AMEN1SMN1; SMN2GAA
SCHEMBL21777215 0.86 ABCC8 (0.41) KMT2AMEN1SMN1; SMN2ALDH1A1LMNA
SCHEMBL30046630 0.85 ALDH1A1 (0.44) NPSR1KMT2AMEN1SMN1; SMN2SCN9A
SCHEMBL21783383 0.85 ALDH1A1 (0.44) NPSR1KMT2AMEN1SMN1; SMN2SCN9A
SCHEMBL21783561 0.81 BRAF (0.40) BRAFBRD4
SCHEMBL30045766 0.76 BRAF (0.41) BRAFBRD4
SCHEMBL21783471 0.76 BRAF (0.41) BRAFBRD4
SCHEMBL31120650 0.74 NPSR1 (0.45) NPSR1KMT2AMEN1SCN9ATSHR
SCHEMBL28557453 0.74 CXCR2 (0.38) NPSR1SMN1; SMN2TSHRALDH1A1HSD17B10
SCHEMBL21783433 0.73 SCN1A (0.37) BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112638879-B Heteroaryl substituted sulfonamide compounds and their use as therapeutic agents 泽农医药公司 2024-06-18 CN disclosed
US-11639351-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. 2023-05-02 US disclosed
US-11639351-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. 2023-05-02 US disclosed
US-10981905-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2021-04-20 US disclosed
US-20200157089-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-05-21 US disclosed
WO-2020047323-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11639351-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents SCN1A, SCN2A, SCN2B NPSR1 455/4885KMT2A 1375/4885MEN1 2925/4885
US-20200157089-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN2A, SCN2B NPSR1 455/4885KMT2A 1375/4885MEN1 2925/4885
US-10981905-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents SCN1A, SCN2A, SCN2B NPSR1 455/4885KMT2A 1375/4885MEN1 2925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.